In adults with active Crohn's disease, activity scores decreased by 143+/-144 points with GH versus 19+/-63 with placebo at four months (P=0.004).
In plain wordsIn adults with active Crohn's disease, GH reduced disease activity scores more than placebo.
- Peptide
- HGH (somatotropin)
- Outcome
- DecreaseCrohn disease activity index change
- Study
n = 34
- Comparator
- Placebo
- Analysis
- Primary
- Outcome group
- Disease Activity · Gastrointestinal
- Studied dose
- 5 mg per day for one week, then 1.5 mg per day · Subcutaneous · Four monthsAs given in this study (human).
Measurements
- Crohns Disease Activity Index decrease
- 143 points
- GH group, +/-144
- Crohns Disease Activity Index decrease
- 19 points
- placebo group, +/-63
Source sentences
At four months, the Crohn's Disease Activity Index score had decreased by a mean of 143+/-144 points in the growth hormone group, as compared with a decrease of 19+/-63 points in the placebo group (P=0.004).
3 context sentences(design, population, supporting numbers)
The primary end point was the change in scores on the Crohn's Disease Activity Index from base line to month 4.
We randomly assigned 37 adults with moderate-to-severe active Crohn's disease to four months of self-administered injections of growth hormone (loading dose, 5 mg per day subcutaneously for one week, followed by a maintenance dose of 1.5 mg per day) or placebo.
We instructed all patients to increase their protein intake to at least 2 g per kilogram of body weight per day.